Healthcare stocks were mixed in afternoon trading, with the
S&P/TSX Healthcare index down 1.1%.
Nordion (NDN.TO): +6.3%
Cardiome Pharma (COM.TO): -1.3%
Aeterna Zentaris (AEZ.TO): +1.6%
Valeant Pharmaceuticals (VRX.TO): -0.4%
Oncolytics Biotech (ONC.TO): -3.1%
In corporate news, Cardiome Pharma said its affiliate has signed
a commercialization agreement with UDG Healthcare for BRINAVESS for
the Irish market. Financial terms weren't disclosed. As agreed, UDG
will fulfill orders and distribute BRINAVESS (vernakalant
intravenous) in Ireland for 3 years.
Also, Aeterna Zentaris has selected Charleston, South Carolina
as its new location for its North American business and global
commercial operations. President and CEO David Dodd said:
"Establishing our North American business and global commercial
activities here is part of our strategic plan not only for the
launch of MACRILEN in the United States...but also for our future
Lastly, Nordion on Monday said that the health science company's
buyer Sterigenics increased the cash consideration to US$12.25 per
share for its issued and outstanding common shares. As previously
announced, the original offer was US$11.75 per share. The total
transaction is now valued at approximately US$758 million. The
board of directors of Nordion determined that the transaction,
including the amendment, is in the best interests of Nordion.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.